{
    "nctId": "NCT01142778",
    "briefTitle": "A Study of Bevacizumab Added to Trastuzumab Plus Docetaxel in the Neoadjuvant Setting in Participants With Early Stage HER2-Positive Breast Cancer",
    "officialTitle": "An Open-Label, Randomized, Multicenter, Phase II, Non Comparative, Exploratory Study on Neoadjuvant Treatment With Trastuzumab Plus Docetaxel Plus Bevacizumab According to Positon Emission Tomography (PET) Value Modification in Patients With Early Stage HER2 Positive Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 152,
    "primaryOutcomeMeasure": "Percentage of Participants With Pathological Complete Response as per Chevallier's Classification as Reviewed by an Independent Committee",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Participants with early stage HER2-positive breast cancer\n* Scheduled to receive neoadjuvant therapy with the objective of conservative surgery\n* Eastern Cooperative Oncology Group (ECOG) performance status 0, 1 or 2\n\nExclusion Criteria:\n\n* Participants with partial or total lobular carcinoma\n* Participants with inflammatory breast cancer\n* Previous treatment with chemotherapy, radiation therapy or hormonal therapy for breast cancer\n* Previous history of cancer (other than curatively treated basal and squamous cell carcinoma of the skin and/or in situ carcinoma of the cervix) relapsing within the 5 years before study entry or in situ contralateral breast carcinoma",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}